Key takeaways
- Afamelanotide, the drug name for Melanotan I, is FDA approved as Scenesse, a 16 mg implant for one rare light-sensitivity disease.
- The approval covers adults with erythropoietic protoporphyria (EPP), not tanning, not children and not any other skin condition.
- The implant is placed under the skin every 2 months by a trained clinician; research vials are a different product with no approval.
- Even for the approved implant, the FDA required years of follow-up to watch for skin cancer.
Melanotan I has an unusual status among research peptides. Under its drug name, afamelanotide, it is an approved medicine in the US, the EU and several other countries. That fact gets repeated a lot, often as if it says something about the vials sold for research.
It doesn't. The approval is for one specific product, for one rare disease, given in one specific way. This post walks through what the FDA actually approved, what the evidence behind it shows, and where the line sits between Scenesse and a vial of powder.
What afamelanotide is and what it does
Melanotan I is a lab-made version of α-MSH, the hormone that tells skin to make melanin. It activates the melanocortin-1 receptor (MC1R) on pigment cells, increasing dark eumelanin. That darkens the skin and adds some protection against light, independent of UV exposure.
Compared with Melanotan II, it is more selective for that pigment receptor. That's why it mostly tans, without the strong sexual and appetite effects MT-II is known for. As a free peptide its half-life is short, which is one reason the approved product is a slow-release implant dosed every 2 months.
What the FDA approved in 2019
The FDA approved Scenesse (afamelanotide) implant, 16 mg, in October 2019. The approved use is narrow: "to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)" 12.
EPP is a rare inherited condition in which light causes severe, burning skin pain. People with it often organize their lives around avoiding daylight.
The label sets out exactly how it is given. A single 16 mg implant goes under the skin above the hip bone every 2 months, inserted by a healthcare professional who has completed the manufacturer's training program 1. Patients are told to keep using sun and light protection during treatment 1.
The EU authorized the same implant in December 2014 for preventing phototoxicity in adults with EPP. It was approved "under exceptional circumstances" because the disease is so rare that full data could not be collected the usual way 3.
What the trial evidence shows
The approval rests on placebo-controlled trials in people with EPP. In the main US trial (CUV039), 93 adults were followed for 180 days. Those on the implant spent a median 64.1 hours in direct sunlight on pain-free days, against 40.5 hours on a dummy implant 1.
That is a real gain for people whose lives are shaped by light avoidance. But it is a modest one, measured over six months, in a very specific group. The broader trial results were published in the New England Journal of Medicine in 2015 4.
Afamelanotide has also been tested outside EPP. In a randomized trial of 55 people with vitiligo, adding monthly implants to narrowband UVB light therapy sped up repigmentation compared with light therapy alone 5. That is a small study, and vitiligo is not an approved use.
What the approval does not cover
The limits matter as much as the approval itself:
- Not tanning. The approvals are for EPP only; none covers cosmetic tanning or skin-cancer prevention in the general public 13.
- Not children. The label says safety and effectiveness have not been established in pediatric patients 1.
- Not self-injection. The approved form is a solid implant placed by a trained clinician, not a powder mixed and injected at home 1.
- Not other conditions. Vitiligo and other uses remain experimental.
The label also flags risks that apply to the approved product. In the EPP trials, implant site reactions (21% vs 10% on placebo) and nausea (19% vs 14%) were the most common side effects 1. Serious allergic reactions, including anaphylaxis, have been reported since approval 1.
Because the drug darkens existing moles and freckles, the label recommends a full body skin exam twice a year 1. When the FDA approved it, it required a registry study following US patients for at least eight years, with skin cancer as a primary concern 2.
Why research vials are a different thing
A vial labeled "Melanotan I" contains, at best, the same peptide sequence as afamelanotide. That is where the overlap ends. The approved product is a specific controlled-release implant made under drug manufacturing rules, with a fixed 16 mg dose given every 2 months 1.
Research vials are freeze-dried powder sold for laboratory use. They are not approved for any human use, and their purity and dose accuracy depend entirely on the seller. Injecting a short-lived peptide from a vial is a different exposure pattern from an implant, so the trial results and safety data for Scenesse do not transfer to it.
The site's evidence rating for Melanotan I (4 out of 5) reflects the Phase 3 implant trials in EPP. It is not a rating of self-injected vials, which have never been studied as such.
The bottom line
Afamelanotide is a genuine approved drug, but only as the Scenesse implant, only for adults with EPP, and only given by trained clinicians. The approval says nothing about tanning, and nothing about the safety or quality of research vials. Even the approved product comes with skin-check advice and long-term cancer monitoring.
This is educational information, not medical advice.
Sources
- SCENESSE (afamelanotide) implant, prescribing information (revised 08/2024) — U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210797s007lbl.pdf
- NDA 210797 approval letter, Scenesse (afamelanotide) implant — U.S. Food and Drug Administration, October 2019. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210797Orig1s000ltr.pdf
- Scenesse: EPAR (European public assessment report) — European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse
- Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria — New England Journal of Medicine, July 2015. https://pubmed.ncbi.nlm.nih.gov/26132941/
- Lim HW et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial — JAMA Dermatology, January 2015. https://pubmed.ncbi.nlm.nih.gov/25230094/
